Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Ascendis Pharma A/SNASDAQ: ASND

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) growth accelerates

Q3 FY2026 weighted avg shares (diluted) of 68.71M shares rose 12.7% year over year, ahead of the +7.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.7% holds above the trailing-twelve-month pace of +7.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
68.71M+0.6% QoQ
Last fiscal yearDec 2025
60.61M+4.7% YoY
LTMSep 2026
65.73M+7.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.7%——
1 year+4.7%——
3-year CAGR+2.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
60.61M EUR
Year-over-year change
+4.7%
4-year CAGR
+2.6%

Weighted Avg Shares (Diluted) vs competitors

How ASND compares with its peers on the latest reported figures

  • ASND's LTM Sep 2026 weighted avg shares (diluted) of 65.73M shares is the 7th highest of the 11 companies compared; the peer median is 101.75M shares.
  • Its year-over-year change of +7.4% is the 5th highest of 11, against a peer median of +5.5%.
  • Over three fiscal years its annual growth of +2.6% compares with a peer median of +4.6%.
ASND Competitors Peer median
Weighted Avg Shares (Diluted) for ASND and competitors
Company Period LTM YoY 3-year CAGR
INSMInsmed IncorporatedLTM Jun 2026214.47M +18.7%+20.2%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026195.7M +0.1%+1.5%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026172.82M +15.4%+8.4%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026115.53M -2.2%+1.1%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026103.83M +1.6%+1.2%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
ASNDAscendis Pharma A/SLTM Sep 202665.73M +7.4%+2.6%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +4.3%+15.0%
UTHRUnited Therapeutics CorporationLTM Jun 202647.05M -3.0%-0.4%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.0%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 202644.83M +33.4%+4.6%
Peer median (excluding ASND) 101.75M+5.5%+4.6%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.